Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma
Rodabe N. Amaria, MD from the University of Texas MD Anderson Cancer Center, Houston, TX summarizes results on a recent randomized Phase II clinical trial of neoadjuvant treatment with BRAF and MEK in...
Author: VJOncology
Added: 02/16/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Clinical Trials | Melanoma | Neoadjuvant Therapy | Skin Cancer | Texas University